Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
Regeneron Japan said on July 29 that it has filed for Japanese approval of DB-OTO (lunsotogene parvec), a gene therapy for hearing loss caused by biallelic variants in the OTOF gene. DB-OTO is the world’s first dual adeno-associated virus (AAV)…
To read the full story
Related Article
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
BUSINESS
- Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
- Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
- Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
- Sumitomo Universal Flu Vaccine Shows Favorable Safety in Europe PI
October 1, 2026
- Rohto Wins Japan Sales Rights to PharmaBio’s Cell Sheet
October 1, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…